Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Monday, 20 May 2024, 10:32

In the latest update, Sonnet BioTherapeutics shared promising clinical data for the SON-1010 treatment, both as a standalone therapy and in combination with an anti-PD-L1. The announcement also included plans to increase the dose-escalation target, showing the company's commitment to advancing its treatment options. The positive results suggest potential benefits for patients and highlight the ongoing progress in developing innovative therapies in the biopharmaceutical sector.

https://store.livarava.com/90b90759-16ae-11ef-a6c2-63e1980711b2.jpg — Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Sonnet BioTherapeutics Announces Updated Clinical Data

Sonnet BioTherapeutics provides an update on the latest clinical data for the SON-1010 treatment. The results show promising outcomes for patients receiving this therapy.

Increased Dose-Escalation Target

The company also plans to raise the dose-escalation target, indicating enhanced treatment strategies in the pipeline.

Improved outcomes for patients
Progress in developing innovative therapies

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.